Supplementary Table 1. Dose Reductions for Treatment-Related Toxicity at Each Dose Level

	Dose Level: CBP501 (mg/m^2)/ cisplatin (mg/m^2)/ nivolumab (mg)			
	16/ 60/ 240 N=3	**16/ 75/ 240 N=6**	**25/ 60/ 240 N=35**	**25/ 75/ 240 N=3**
CBP501 reduced (%)	0	1 (17%)	4 (11%)	1 (33%)
Cisplatin reduced (%)	1 (33%)	2 (33%)	7 (20%)	2 (67%)

British Journal of Cancer Research
2024;7(1): 648-655. doi:10.31488/bjcr.189

Supplementary Table 2. Summary of Grade ≥ 3 AEs by System Organ Class and Preferred Term by Dose Cohort each patient reported once per preferred term

MedDRA SOC Preferred Term	Dose Level: CBP501 (mg/m^2)/ cisplatin (mg/m^2)/ nivolumab (mg)				
	16/ 60/ 240 N=3	16/ 75/ 240 N=6	25/ 60/ 240 N=35	25/ 75/ 240 N=3	Total N=47
	n (%)				
Patients with any Grade ≥ 3 AE	**2 (66.7)**	**6 (83.3)**	**28 (74.3)**	**2 (66.7)**	**38 (80.9)**
Blood & lymphatic system disorders	**1 (33.3)**	**4 (66.7)**	**21 (60.0)**	**0**	**26 (55.3)**
Anemia	1	2	12	1	16 (34.0)
Leukopenia[A]	0	0	4	0	4 (8.5)
Lymphopenia[B]	0	2	9	1	12 (25.5)
Neutropenia[C]	0	0	4	0	4 (8.5)
Thrombocytopenia[D]	0	0	3	0	3 (6.4)
Gastrointestinal disorders	**1 (33.3)**	**1 (16.7)**	**9 (25.7)**	**0**	**11 (23.4)**
Abdominal pain	1	0	4	0	5 (10.6)
Diarrhea	0	1	1	0	2
Diarrhea hemorrhagic	0	0	1	0	1
Duodenal obstruction	0	0	1	0	1
Gastritis erosive	0	0	1	0	1
GI hemorrhage	0	0	2	0	2
Lower GI hemorrhage	0	0	2	0	2
Small intestinal obstruct.	0	0	1	0	1
General disorders	**1 (33.3)**	**0**	**3 (8.6)**	**0**	**4 (8.5)**
Asthenia	1	0	0	0	1
Fatigue	1	0	2	0	3 (6.4)
Pyrexia	0	0	1	0	1
Hepatobiliary disorders	**0**	**0**	**1 (2.9)**	**0**	**1 (2.1)**
Hepatic failure	0	0	1	0	1
Infections & infestations	**1 (33.3)**	**1 (16.7)**	**1 (2.9)**	**0**	**3 (6.4)**
Influenza	0	1	0	0	1
Kidney infection	0	0	1	0	1
Sepsis	1	0	0	0	1
Injury, poisoning & procedural complications	**1**	**0**	**2 (5.7)**	**0**	**3 (6.4)**
Infusion related reaction[E]	1	0	1	0	2
Lower limb fracture	0	0	1	0	1
Investigations	**0**	**0**	**3 (8.6)**	**2 (66.7)**	**11 (23.4)**
ALP increased	0	0	0	1	1
ALT increased	0	0	2	0	2
AST increased	0	0	2	1	3 (6.4)
Bilirubin increased	0	0	1	1	2
Troponin T increased	0	0	1	0	1
Metabolism & nutrition disorders	**1 (33.3)**	**3 (50.0)**	**7 (20.0)**	**1 (33.3)**	**11 (23.4)**
Dehydration	0	1	0	0	1
Hyperglycemia	0	0	0	1	1
Hypoalbuminemia	0	0	3	1	4 (8.5)
Hypocalcemia	1	0	1	0	2
Hypokalemia	0	0	2	0	2
Hypomagnesemia	0	0	1	0	1

Hyponatremia	0	2	4	1	7 (14.9)
Hypophosphatemia	0	0	1	0	1
Musculoskeletal & connective tissue disorders	**0**	**0**	**3 (8.6)**	**0**	**3 (6.4)**
Back pain	0	0	1	0	1
Flank pain	0	0	1	0	1
Muscular weakness	0	0	1	0	1
Nervous system disorders	**1 (33.3)**	**0**	**1 (2.9)**	**0**	**2 (4.3)**
Encephalopathy	1	0	0	0	1
Syncope	0	0	1	0	1
Psychiatric disorders	**1 (33.3)**	**0**	**0**	**0**	**1 (2.1)**
Mental status changes	1	0	0	0	1
Renal & urinary disorders	**0**	**1 (16.7)**	**2 (5.7)**	**0**	**3 (6.4)**
Acute kidney injury[F]	0	2	2	0	4 (8.5)
Hydronephrosis	0	0	1	0	1
Respiratory, thoracic & mediastinal disorders	**0**	**0**	**1 (2.9)**	**0**	**1 (2.1)**
Dyspnea	0	0	1	0	1
Vascular disorders	**1 (33.3)**	**0**	**5 (14.3)**	**0**	**6 (12.8)**
Deep vein thrombosis	0	0	1	0	1
Embolism	0	0	1	0	1
Hypertension	0	0	2	0	2
Hypotension	1	0	1	0	2

A: Includes cases based on white blood cell count decreased, graded per NCI CTCAE v4.03

B: Includes cases based on lymphocyte count decreased, graded per NCI CTCAE v4.03

C: Includes cases based on granulocyte or neutrophil count decreased, graded per NCI CTCAE v4.03 Includes cases based on platelet count decreased, graded per NCI CTCAE v4.03

D: Includes cases based on white blood cell count decreased, graded per NCI CTCAE v4.03

E: Includes cases for anaphylactic reaction, cytokine release syndrome, urticaria, erythema, pruritis, flushing, rash F: Includes cases based on creatinine increased, graded per NCI CTCAE v4.03

ALP: alkaline phosphatase; ALT: alanine aminotransferase; AST: aspartate aminotransferase; GI: gastrointestinal

Supplementary Table 3. Analysis of Paired Biopsies and Efficacy Outcomes

Pancreatic Cancer	CD8 Infiltration		PD-L1 Expression		PD-L1 antibody	PFS (months)	OS (months)
	Pre-treatment	In cycle 2	Pre-treatment	In cycle 2			
Patient A	0%	1-5%	20%	50%	28.8	5.8	5.8
Patient B	<0.1%	1-2%	NA	1%	28-8	8.0	8.0
Patient C	2%	2%	NA	NA	28-8	1.3	4.3
Patient D	20%	5%	0%	0%	SP142	2.0	2.3
Colo-rectal Cancer	CD8 Infiltration		PD-L1 Expression		PD-L1 antibody	PFS (months)	OS (months)
	Pre-treatment	In cycle 2	Pre-treatment	In cycle 2			
Patient E	3%	5%	0%	0%	28-8	1.4	11.8
Patient F	<1%	10%	0%	0%	SP142	1.4	>4.7
Patient G	2%	NA	0%	NA	28-8	1.4	16.8
Patient H	3%	NA	0%	0%	28-8	1.3	9.0

PD: progressive disease; PFS: progression-free survival; SD: stable disease

Supplementary Table 4. Survival Outcomes for Patient Cohorts Treated with CBP501 Combination Therapy

ClinicalTrials.gov Identifier	NCT03113188	NCT00551512	NCT00700336	NCT00942825
Study code	CBP17-01	CBP06-01	CBP08-01	CBP08-02
Tumor Type/ Indication	Relapsed/refractory pancreatic cancer	Platinum refractory/resistant ovarian cancer	Chemo-naïve malignant pleural mesothelioma	Chemo-naive non-squamous non-small cell lung cancer
Regimen	CBP501 + cisplatin + nivolumab	CBP501 + cisplatin	CBP501 + cisplatin + pemetrexed	CBP501 + cisplatin + pemetrexed
All treated, n	24	14	40	96
Efficacy population, n	14	14	40	96
PFS, median (95% CI), months	2.4 (1.3, 4.6)*	3.3 (2.4, 4.0)#	5.9 (4.3, 7.2)*	4.7 (3.6,5.7)*
OS, median (95% CI), months	4.9 (3.4, 6.8)*	Not reached	13.3 (11.1,15.3)#	15.2 (11.0,18.0)*
Subsets with WBC ≤ / >10,000/mm^3 at screening, n	11 / 3	12 / 2	28 / 12	71 / 25
OS or PFS, median (95% CI), months for subset with WBC ≤10,000/mm^3	OS 5.8 (4.2, 8.0)*	PFS 4.4 (3.2,5.5)#	PFS 7.2 (5.8,8.5)#	OS 17.3 (15.1,19.3)#

OS or PFS, median (95% CI), months for subset with WBC >10,000/mm^3	OS 3.4[#]	PFS 1.3[#]	PFS 4.2 (3.0,5.2)[#]	OS 6.3 (4.9,7.4)[#]
Logrank Hazard Ratio, WBC ≤ vs > 10,000/μL, (95% CI)	OS 0.28 (0.035, 2.2)[#]	PFS 0.093 (0.0014, 6.3)[#]	PFS 0.34 (0.13, 0.90)[#]	OS 0.35 (0.17, 0.74)[#]
Logrank (Mantel-Cox) p value	0.0213[#]	<0.0001[#]	0.0013[#]	<0.0001[#]

Numbers calculated by SAS[*] or GraphPad Prism 9[#]

CI: confidence interval; OS: overall survival; PFS: progression-free survival; WBC: white blood cell count



Supplementary Figure 1



Supplementary Figure 2

To cite this article: Matrana M, Tsai F, Satti S, Borazanci EH, Moser JC, Do K, et al. Clinical Significance of Serum miR-21, CA153 and CEA in Breast Cancer. British Journal of Cancer Research. 2024; 7(1): 648- 655. doi: 10.31488/bjcr.189.